Table 2 Comparison of clinical data of recipients with grafts from donors > 40 years.
Variables | Non-macrosteatotic grafts | Macrosteatotic grafts | ||
|---|---|---|---|---|
Other combinations (n = 52) | Female to male (n = 42) | Other combinations (n = 51) | Female to male (n = 42) | |
Graft factors | ||||
Donor age (years) | 48 (42–52) | 45 (42–48) | 48 (44–53) | 51 (45–55) |
ABO blood type incompatible donor | 6 (11.5) | 4 (9.5) | 5 (9.8) | 12 (28.6)# |
Graft ischemia time (min)* | 119 (103–139) | 127 (108–163) | 117 (101–135) | 126 (102–146) |
Graft-to-recipient weight ratio < 0.8%** | 5 (9.6) | 6 (14.3) | 3 (5.9) | 7 (16.7) |
Laparoscopic procurement | 1 (1.9) | 1 (2.4) | 0 | 2 (4.8) |
Hepatic inflow occlusion*** | ||||
0 round | 23 (44.2) | 21 (50.0) | 28 (54.9) | 17 (40.5) |
1–2 rounds | 14 (26.9) | 16 (38.1) | 12 (23.5) | 13 (31.0) |
≥ 3 rounds | 15 (28.8) | 5 (11.9) | 11 (21.6) | 12 (28.6) |
Recipient factors | ||||
Age (years) | 51 (43–57) | 48 (46–53) | 52 (43–62) | 51 (44–57) |
Body mass index (kg/m2) | 23.7 (21.3–26.1) | 24.0 (22.2–25.7) | 24.5 (22.1–26.6) | 23.9 (21.2–25.7) |
Hypertension | 5 (9.6) | 4 (9.5) | 7 (13.7) | 9 (21.4) |
Diabetes | 16 (30.8) | 18 (42.9) | 25 (49.0) | 16 (38.1) |
Hepatitis B virus prophylaxis era | ||||
Monoprophylaxis (2002–2007) | 2 (3.8) | 6 (14.3) | 4 (7.8) | 2 (4.8) |
Entecavir (2008–2011) | 21 (40.4) | 17 (40.5) | 22 (43.1) | 11 (26.2) |
Entecavir (2011–2014) | 29 (55.8) | 19 (45.2) | 25 (49.0) | 29 (69.0) |
Non-viral etiology | 14 (26.9) | 5 (11.9)# | 16 (31.4) | 6 (14.3) |
Hepatocellular carcinoma | ||||
None | 34 (65.4) | 18 (42.9)# | 27 (52.9) | 16 (38.1)# |
Within the Milan criteria | 15 (28.8) | 14 (33.3) | 20 (39.2) | 16 (38.1) |
Beyond the Milan criteria | 3 (5.8) | 10 (23.8) | 4 (7.8) | 10 (23.8) |
MELD score | 17 (10–34) | 15 (11–28) | 16 (12–33) | 14 (10–22) |
Neutrophil-to-lymphocyte ratio | 3.4 (2.2–6.0) | 2.9 (1.7–6.3) | 2.6 (1.5–6.1) | 2.6 (1.7–4.1) |
Albumin (g/dL) | 3.1 (2.7–3.7) | 3.0 (2.7–4.1) | 3.1 (2.6–3.6) | 3.3 (2.9–3.9) |
Platelet count (× 109/L) | 85 (64–125) | 58 (38–84) | 71 (46–119) | 67 (39–133) |
Refractory ascites | 12 (23.1) | 12 (28.6) | 16 (31.4) | 6 (14.3) |
Hepatic encephalopathy | ||||
None | 39 (75.0) | 35 (83.3) | 41 (80.4) | 34 (81.0) |
Grade I–II | 8 (15.4) | 6 (14.3) | 7 (13.7) | 5 (11.9) |
Grade III–IV | 5 (9.6) | 1 (2.4) | 3 (5.9) | 3 (7.1) |
Preoperative continuous renal replacement | 3 (5.8) | 2 (4.8) | 2 (3.9) | 1 (2.4) |
Operative time (min) | 547 (489–606) | 568 (530–649)# | 556 (495–603) | 594 (517–643)# |
Perioperative transfusion**** | ||||
Packed red blood cells (units) | 4 (2–8) | 3 (1–11) | 6 (3–11) | 6 (2–10) |
Apheresis platelets (units)***** | 1.2 (0–2.7) | 2.0 (0–4.2) | 2.0 (0–3.7) | 1.3 (0–4.0) |
Fresh frozen plasma (units) | 6 (2–7) | 6 (2–11) | 4 (2–8) | 5 (2–8) |
Cryoprecipitate (units) | 6 (0–9) | 6 (0–8) | 6 (0–6) | 0 (0–6)# |
